Previous 10 | Next 10 |
Yesterday, investors discovered the likely reason for the strange recent weakness in Theravance ( TBPH ), despite the neutral or even good news flow: Neil Woodford has been ousted and his flagship fund - which holds the bulk of his large TBPH stake - will be liquidated by BlackRock: "bec...
DUBLIN , Sept. 25, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 , at 7:45 a.m. ET . The conference will take place Oct...
Initial data from a Phase 1 clinical trial evaluating single and multiple ascending doses of Theravance Biopharma's ( TBPH -0.1% ) inhalable JAK inhibitor TD-8236 in healthy volunteers and patients with mild asthma showed a favorable safety profile. More news on: Theravance Biopharm...
DUBLIN , Sept. 9, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced initial results, including positive biomarker responses, from its Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical ...
I have always found that mercy bears richer fruits than strict justice ." - Abraham Lincoln We continue our series of reviews of Q2 results at previously profiled small biotech concerns today. In today's post, we revisit Theravance Biopharma ( TBPH ) whose stock has been on a nice little ...
This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 08/13/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for a...
Theravance Biopharma, Inc. (TBPH) Q2 2019 Earnings Conference Call July 31, 2019, 08:00 ET Company Participants Jessica Stitt - Former VP, Finance and IR Rick Winningham - Chairman & CEO Brett Haumann - SVP, Clinical Development & Chief Medical Officer Frank Pasqualone ...
The following slide deck was published by Theravance Biopharma, Inc. in conjunction with their 2019 Q2 earnings Read more ...
Theravance Biopharma (NASDAQ: TBPH ): Q2 GAAP EPS of -$0.72 beats by $0.50 . More news on: Theravance Biopharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
DUBLIN , July 31, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the second quarter ended June 30, 2019 . Revenue for the second quarter of 2019 was $26.2 million . Second quarter operating lo...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
2024-04-12 08:00:07 ET Julian Harrison from BTIG issued a price target of $21.00 for TBPH on 2024-04-12 06:36:00. The adjusted price target was set to $21.00. At the time of the announcement, TBPH was trading at $8.93. The overall price target consensus is at $14.00 with...
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 PR Newswire DUBLIN , ...